Suppr超能文献

基于1,2,3,4-四氢异喹啉的CXCR4拮抗剂的合成与构效关系

Synthesis and SAR of 1,2,3,4-Tetrahydroisoquinoline-Based CXCR4 Antagonists.

作者信息

Wilson Robert J, Jecs Edgars, Miller Eric J, Nguyen Huy H, Tahirovic Yesim A, Truax Valarie M, Kim Michelle B, Kuo Katie M, Wang Tao, Sum Chi Shing, Cvijic Mary E, Paiva Anthony A, Schroeder Gretchen M, Wilson Lawrence J, Liotta Dennis C

机构信息

Department of Chemistry, Emory University, 1515 Dickey Drive NE, Atlanta, Georgia 30322, United States.

Bristol-Myers Squibb Research & Development, Princeton, New Jersey 08543, United States.

出版信息

ACS Med Chem Lett. 2017 Dec 8;9(1):17-22. doi: 10.1021/acsmedchemlett.7b00381. eCollection 2018 Jan 11.

Abstract

CXCR4 is the most common chemokine receptor expressed on the surface of many cancer cell types. In comparison to normal cells, cancer cells overexpress CXCR4, which correlates with cancer cell metastasis, angiogenesis, and tumor growth. CXCR4 antagonists can potentially diminish the viability of cancer cells by interfering with CXCL12-mediated pro-survival signaling and by inhibiting chemotaxis. Herein, we describe a series of CXCR4 antagonists that are derived from ()-5,6,7,8-tetrahydroquinolin-8-amine that has prevailed in the literature. This series removes the rigidity and chirality of the tetrahydroquinoline providing 2-(aminomethyl)pyridine analogs, which are more readily accessible and exhibit improved liver microsomal stability. The medicinal chemistry strategy and biological properties are described.

摘要

CXCR4是在许多癌细胞类型表面表达的最常见趋化因子受体。与正常细胞相比,癌细胞过度表达CXCR4,这与癌细胞转移、血管生成和肿瘤生长相关。CXCR4拮抗剂可通过干扰CXCL12介导的促生存信号和抑制趋化作用来潜在地降低癌细胞的活力。在此,我们描述了一系列源自文献中常见的()-5,6,7,8-四氢喹啉-8-胺的CXCR4拮抗剂。该系列消除了四氢喹啉的刚性和手性,提供了2-(氨基甲基)吡啶类似物,其更容易获得且具有改善的肝微粒体稳定性。描述了药物化学策略和生物学特性。

相似文献

1
Synthesis and SAR of 1,2,3,4-Tetrahydroisoquinoline-Based CXCR4 Antagonists.基于1,2,3,4-四氢异喹啉的CXCR4拮抗剂的合成与构效关系
ACS Med Chem Lett. 2017 Dec 8;9(1):17-22. doi: 10.1021/acsmedchemlett.7b00381. eCollection 2018 Jan 11.
10
The CXCL12-CXCR4 chemokine pathway: a novel axis regulates lymphangiogenesis.CXCL12-CXCR4 趋化因子通路:调控淋巴管生成的新轴。
Clin Cancer Res. 2012 Oct 1;18(19):5387-98. doi: 10.1158/1078-0432.CCR-12-0708. Epub 2012 Aug 29.

本文引用的文献

2
Chemokines in cancer.趋化因子与癌症。
Cancer Immunol Res. 2014 Dec;2(12):1125-31. doi: 10.1158/2326-6066.CIR-14-0160.
3
Discovery of tetrahydroisoquinoline-based CXCR4 antagonists.基于四氢异喹啉的CXCR4拮抗剂的发现。
ACS Med Chem Lett. 2013 Sep 5;4(11):1025-30. doi: 10.1021/ml400183q. eCollection 2013 Nov 14.
4
Small molecule inhibitors of CXCR4.CXCR4 的小分子抑制剂。
Theranostics. 2013;3(1):47-75. doi: 10.7150/thno.5376. Epub 2013 Jan 15.
10
CXCL12 (SDF-1)/CXCR4 pathway in cancer.CXCL12(SDF-1)/CXCR4 通路与癌症。
Clin Cancer Res. 2010 Jun 1;16(11):2927-31. doi: 10.1158/1078-0432.CCR-09-2329. Epub 2010 May 18.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验